Fastin (phentermine hydrochloride) is a prescription medication indicated as a short-term adjunct in the comprehensive management of exogenous obesity. The primary goal of treatment is to assist in weight reduction. This support is strictly provided alongside an established regimen that includes caloric restriction, increased physical activity, and behavioral modification, as determined by a healthcare provider.

The medication is used to support individuals whose weight management requires temporary assistance for appetite control, which helps in adhering to a low-calorie diet. The typical usage period is limited to a few weeks, reflecting the approved scope of treatment for this therapeutic domain. The usefulness of agents in this class should be considered carefully against potential risks, emphasizing the necessity of medical supervision.

---

Quick Fact: Relief for Appetite/Hunger

• Therapeutic Use: Short-term support for weight reduction
• Indication Category: Management of exogenous obesity

Who Can and Cannot Use Fastin?

Eligibility for Fastin (phentermine) is strictly defined by regulatory labeling for short-term use as an adjunct in a weight-reduction regimen. The medication is indicated for adults with an initial Body Mass Index (BMI) of 30 kg/m^2 or a BMI geq 27 kg/m^2 with at least one controlled risk factor, such as controlled hypertension or diabetes.

---

Absolute Contraindications

Use is absolutely contraindicated in patients with specific high-risk conditions, including:

Category	Contraindicated Conditions
Cardiovascular	Advanced arteriosclerosis, symptomatic cardiovascular disease, uncontrolled hypertension, or primary pulmonary hypertension.
Physiological	Pregnancy, lactation, hyperthyroidism, or glaucoma.
Psychiatric	Agitated states or a history of drug abuse.
Concurrent Drug	Use during or within 14 days of taking a Monoamine Oxidase Inhibitor (MAOI).

---

Population Restrictions

Safety and effectiveness are not established for use in pediatric patients (age 16 and younger), and its use is not recommended in this population. Caution and potential dose adjustment are required for elderly patients and those with renal impairment.

Interactions with Other Medicines and Products

This section outlines the officially documented interaction patterns for Fastin (Phentermine hydrochloride) based strictly on government regulatory labeling. The interactions are defined primarily by pharmacodynamic conflicts and changes in drug clearance.

Regulatory Interaction Restrictions

Category	Restriction and Official Description
Absolute Contraindication	Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated, with this combination prohibited for 14 days following the use of an MAOI due to the risk of hypertensive crisis.
Not Recommended Combinations	Co-administration with Other Anorectic Agents or Herbal Products for Weight Loss is not recommended by regulatory authorities.

Pharmacodynamic and Pharmacokinetic Interactions

Co-administration with Adrenergic Neuron Blocking Drugs may result in a decrease in the hypotensive effect of the latter medication. For patients using Insulin or Oral Hypoglycemics, the requirements for these medications may be altered as a consequence of weight loss achieved during Fastin therapy.

Systemic Exposure of phentermine is highly dependent on urinary pH. Regulatory documents note that co-administration with substances that alter urine acidity or alkalinity can significantly modify the drug’s renal clearance, leading to increased or decreased systemic plasma levels. Furthermore, the concomitant use of alcohol may result in an adverse drug interaction according to official labeling. Special caution is noted for patients with Renal Impairment, where increased exposure is expected due to reliance on urinary excretion.

Fastin's active ingredient, Clotrimazole, functions by disrupting the essential biological machinery of the fungal cell, initiating a cascade that results in structural compromise and inhibition of cellular proliferation. The drug's mechanism operates through two primary mechanistic domains.

---

Targeting the Fungal Sterol Biosynthesis Pathway

Clotrimazole acts as a non-competitive inhibitor of the enzyme lanosterol 14alpha-demethylase (14alpha-DM), a crucial component for synthesizing ergosterol, which serves as the fungal cell membrane's structural sterol. This molecular targeting is the initiating step in the mechanistic cascade, blocking the supply of ergosterol and causing precursor molecules to accumulate.

---

Inducing Fungal Cell Membrane Structural Failure

This depletion of ergosterol, combined with the buildup of toxic, abnormal sterols, leads to a profound increase in fungal cell membrane permeability. This structural failure causes the irreversible leakage of essential intracellular contents and the collapse of the organism's necessary homeostatic processes. The resulting physiological effect is a loss of cellular viability, manifesting as a fungistatic (inhibition of growth) or fungicidal (cellular death) consequence.

The administration of Fastin (Phentermine Hydrochloride) is strictly limited to the oral route and is prescribed as a short-term adjunct to weight management. Treatment duration is typically limited to a few weeks, as specified in the approved scope of use, and the medication must be discontinued if a patient develops tolerance to the appetite-suppressing effect.

Dosage and Timing

Standard dosing regimens typically utilize a range between 15 mg and 37.5 mg taken once per day. The specific schedule depends on the dosage form used. For once-daily administration, the dose is taken either before breakfast or one to two hours after breakfast. Alternatively, some regimens specify lower, divided doses taken three times per day, approximately 30 minutes before meals. Crucially, the medication must not be taken late in the evening to avoid disrupting sleep patterns.

Administration Considerations

The formulation dictates specific handling requirements. For example, extended-release capsules must be swallowed whole and must not be chewed, crushed, or split, ensuring the correct delivery of the active ingredient. Conversely, scored tablets can often be split if a partial dose is required. For certain patient populations, caution is warranted; the medication is generally not recommended for use in patients 16 years of age and under. Furthermore, older adults and individuals with renal impairment may require a lower starting dose or careful adjustment due to expected changes in how the body processes the drug.

Research evidence / Overview of studies for Fastin

---

Evidence for Short-Term Adjunct Treatment in Exogenous Obesity

The primary research for Fastin (phentermine) focuses on its approved use as a temporary adjunct for weight reduction when used alongside a comprehensive program of diet and physical activity in eligible adults. The most rigorous evidence is derived from short-term, placebo-controlled Randomized Controlled Trials (RCTs), where participants received either Fastin or an inactive substance (placebo) in conjunction with the prescribed lifestyle changes. These trials were designed to examine how outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level changed over the study period.

Studies generally examined outcomes related to temporary physiological imbalance in adults with obesity (a BMI of 30 kg/m^2 or higher) or those who are overweight (a BMI of 27 kg/m^2 or higher) who also have weight-related health issues like high blood pressure or high cholesterol. Findings describe patterns observed in the studies; researchers monitored changes in participants' body weight over the study intervals. This research provides context but not individual predictions, and the findings help contextualize how patients reported their experience during the short treatment periods.

---

Outcomes Studied in Clinical Trials

The research examined patient-reported outcomes describing perceived discomfort and monitoring physiological strain or stress. Researchers primarily looked at change in body weight, measuring the difference from baseline or as a percentage of the person’s starting weight. They also evaluated how many participants met a specific, predefined threshold for change in body weight, such as a 5% or 10% reduction from initial body weight.

Studies also explored other measures, including metabolic parameters like blood sugar and blood pressure, which are outcomes related to systemic function. While these findings indicate how symptoms evolved in the observed populations, the results apply only to the specific conditions and populations studied, which were generally selected and closely monitored.

---

The Landscape of Evidence Gaps and Remaining Uncertainty

The research describes limitations that scientists and regulators have noted. One key limitation is that follow-up durations were limited, making it difficult to fully understand long-term effects. The results from the initial pivotal trials were often based on sample sizes that were modest in size, which contributes to the variability and scope of the evidence.

Evidence quality varies across studies, and findings showed variability across some studies. A significant research gap is the limited data from large, long-term studies that look beyond weight measurements to examine associations between treatment and major cardiovascular events (such as heart attack or stroke) or other severe health outcomes over many years. The research provides context but does not determine whether an individual will respond similarly, and the duration of efficacy is not fully characterized.

Key Studies & References

1. PHENTERMINE HYDROCHLORIDE TABLETS USP, 37.5 mg CIV - Official Drug Label (Indications and Usage, Limitations, Short-Term Focus)

Common questions about Fastin (FAQ)

---

Q: What is Fastin used for?

A: Fastin is a brand name of the drug phentermine, which is approved for the short-term management of exogenous obesity. It is used as an addition to a comprehensive weight reduction program that includes exercise, behavioral modification, and a reduced-calorie diet.

---

Q: How does phentermine work?

A: Phentermine is classified as a sympathomimetic amine. Its action in reducing appetite is primarily thought to be due to central nervous system stimulation. It may affect certain neurotransmitter levels, which are believed to influence the regulation of appetite.

---

Q: What are the potential side effects of taking phentermine?

A: Common side effects reported in clinical studies include dry mouth, unpleasant taste, and trouble sleeping (insomnia). Other nervous system effects like restlessness, dizziness, and headache have also been reported. Cardiovascular effects such as palpitations and elevated blood pressure are possible. Gastrointestinal effects like constipation or diarrhea may occur.

---

Q: Are there serious side effects associated with phentermine?

A: Yes, serious but rare side effects have been reported. These include primary pulmonary hypertension and regurgitant cardiac valvular disease. You should seek immediate medical attention if you experience symptoms like chest pain, shortness of breath, unexplained fainting, or swelling in your lower legs or feet.

---

Q: Who should not take phentermine?

A: Phentermine is generally not recommended for individuals with a history of cardiovascular disease (including uncontrolled high blood pressure, heart rhythm problems, or coronary artery disease), hyperthyroidism (overactive thyroid), or glaucoma. It is also not recommended for use by patients with a history of drug abuse. Patients should discuss their full medical history with a healthcare provider before starting treatment.

---

Q: Can phentermine be taken with other weight loss medications?

A: No. The coadministration of phentermine with other medications intended for weight loss is not recommended due to the potential for serious adverse effects, including risks to the heart and lungs.

---

Q: Is phentermine safe to take during pregnancy or while breastfeeding?

A: The safe use of phentermine during pregnancy has not been established. It is generally not recommended for use by women who are pregnant or planning to become pregnant. Furthermore, due to the potential for harm to the infant, a decision must be made to either stop nursing or discontinue the medication, taking into account the importance of the drug to the mother.

Storage and Disposal Requirements

Fastin (phentermine) must be handled according to strict regulatory guidelines to maintain stability and comply with controlled substance requirements.

Storage Conditions

Requirement	Official Mandate
Temperature	Store at controlled room temperature: 20 C to 25 C (68 F to 77 F).
Protection	Keep away from moisture, excess heat, and freezing.
Packaging	Keep the medication in its original, tightly closed container.
Child Safety	Store in a secure, locked location, out of the reach and sight of children.

Disposal Instructions

As a Schedule IV controlled substance, unused or expired Fastin must not be flushed down a toilet or drain. Return it to a drug take-back program or an authorized collector. If these options are unavailable, regulatory guidance permits mixing the medication with an unappealing substance, sealing the mixture in a container, and disposing of it in household trash.